In this randomized controlled clinical trial, 326 patients with ADHD will be investigated regarding the effectiveness of a digital therapeutic for improved ADHD symptomatology, the unguided online intervention attexis. Inclusion criteria are: male, female or non-binary, age 18-65, diagnosis of ADHD, elevated levels of ADHD symptoms (score of ≥17 either on the inattention subscale or on the impulsivity/hyperactivity subscale of the ASRS v1.1), stable treatment for at least 30 days at time of inclusion, sufficient German skills, and consent to participation. Exclusion criteria are: Diagnosis of any other severe psychiatric disorder and plans to change treatment in the upcoming three months. Patients will be randomized and allocated to either an intervention group, receiving access to attexis in addition to TAU, or a control group, receiving access to TAU only. Primary endpoint will be self-rated ADHD symptomatology, assessed via the ASRS v1.1, with three months post-allocation being the primary time point for assessment of effectiveness. Six months post allocation will be used as a timepoint for follow-up assessment of endpoints. Secondary endpoints will be depressive symptoms, self-esteem, work and social functioning, and health-related quality of life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
337
Participants will receive access to the digital health intervention attexis in addition to TAU.
GAIA AG
Hamburg, Germany
ADHD Symptom Severity
ASRS v1.1. Total score ranging from 0-72; higher scores mean more ADHD symptoms (worse outcome).
Time frame: 3 months
Depressive Symptomatology
PHQ-9. Total score ranging from 0-27; higher scores mean more depressive symptomatology (worse outcome).
Time frame: 3 months, 6 months
Self Esteem
Rosenberg Self Esteem Scale (RSES). Total score ranging from 0-30; higher scores mean higher self-esteem (better outcome).
Time frame: 3 months, 6 months
Functioning
Work and Social Adjustment Scale (WSAS). Total score ranging from 0-40; higher scores mean higher impairment (worse outcome).
Time frame: 3 months, 6 months
Health-Related Quality of Life
AQoL-8D. Total score ranging from 0-100; higher scores mean higher quality of life (better outcome).
Time frame: 3 months, 6 months
ADHD Symptom Severity
ASRS v1.1. Total score ranging from 0-72; higher scores mean more ADHD symptoms (worse outcome).
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.